Discover open access scientific publications

Search, annotate, share and cite publications

Publications by W. Brugger

P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-Pd-(L)1 Containing Therapy (HUDSON)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

Related publications

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

OA05.01 Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated With Anti-Pd-(L)1 Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC With Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-32 an Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-08 Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-Pd-1/Pd-L1

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Tetrabenazine as Anti-Chorea Therapy in Huntington Disease: An Open-Label Continuation Study. Huntington Study Group/Tetra-Hd Investigators

BMC Neurology
MedicineNeurology
2009English

SCLE and Dermatomyositis in Anti‐PD‐1 Therapy

British Journal of Dermatology
DermatologyMedicine
2019English

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy